AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0%
Mon, 16 Aug

AUROBINDO PHARMA has announced its results for the quarter ended June 2021. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-20*
3
Mar-21*
3
Jun-21*
QoQ ChangeYoY Change
Net SalesRs m59,24860,01557,020-5.0%-3.8%
Other incomeRs m1,1567811,09940.7%-4.9%
TurnoverRs m60,40460,79658,119-4.4%-3.8%
ExpensesRs m46,67447,26844,926-5.0%-3.7%
Gross profitRs m12,57412,75412,094-5.2%-3.8%
DepreciationRs m2,5552,6602,7975.1%9.5%
InterestRs m211182129-29.3%-38.9%
Profit before taxRs m10,96410,69210,267-4.0%-6.4%
TaxRs m3,0122,5972,477-4.6%-17.7%
Profit after taxRs m7,9528,0967,790-3.8%-2.0%
Gross profit margin%21.221.321.2
Effective tax rate%27.524.324.1
Net profit margin%13.213.313.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 3.8% on a year-on-year (YoY) basis. The expenses were down by 3.7% YoY during the same period.
  • The company's operating profit declined by 3.8% YoY during the quarter. Consequently, operating profit margins remained same and stood at 21.2% in 1QFY22.
  • Depreciation charges increased by 9.5% and finance costs declined by 38.9% YoY, respectively.
  • Other income declined by 4.9% YoY during the quarter.
  • Net profit for the quarter declined by 2.0% YoY. Net profit margins during the quarter increased from 13.2% in 1QFY21 to 13.4% in 1QFY22.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 5.0% on a quarter-on-quarter (QoQ) basis. The expenses were down by 5.0% QoQ during the same period.
  • The company's operating profit declined by 5.2% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 21.2% in 1QFY22 as against 21.3% in 4QFY21.
  • Net profit for the quarter declined by 3.8% QoQ, while net profit margins increased from 13.3% in 4QFY21 to 13.4% in 1QFY22.

To see how AUROBINDO PHARMA has performed over the last eight quarters,please visit here.

Going LIVE Today at 5pm: The EV Gold Rush Special Event

AUROBINDO PHARMA Share Price Performance

Over the last one year, AUROBINDO PHARMA share price has moved down from Rs 878.2 to Rs 736.5, registering a Loss of Rs 141.7 or around 16.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 25,854.9 (down 0.1%). Over the last one year it has moved up from 19,114.4 to 25,854.9, a gain of 6,741 points (up 35.3%).

Overall, the S&P BSE SENSEX is up 44.8% over the year.

Current Valuations

At the current price of Rs 736.5, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 8.0 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.0 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0%". Click here!

  

Related Views on News

AUROBINDO PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of AUROBINDO PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

5 Green Energy Stocks to Watch as India Readies for a Revolution(Views On News)

Oct 13, 2021

The excitement around green energy stocks has opened up a huge contrarian opportunity in the traditional energy space.

Could HDFC Bank be a Big EV Winner? The Answer Will Surprise You...(Profit Hunter)

Oct 13, 2021

Why should investors take it for granted that India's Tesla will be one of the major auto stocks?

Tata Group Stocks are on Fire: Which one Should You Buy?(Profit Hunter)

Oct 15, 2021

Tata group stocks are on fire. Find out which one deserves your attention.

Massive Surge in the Shares of Tata Motors Today. Key Factors Favouring the Rally(Views On News)

Oct 13, 2021

Tata Motors zooms 23% after report of TPG investing Rs 75 bn in EV arm.

India's Big PSU Selloff: Watch Out for these Top Stocks(Views On News)

Oct 15, 2021

The government's plan to divest its stakes in PSUs could spark off a rally in these four stocks.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 25, 2021 03:36 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - SYSCHEM (I). COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS